Endocrine therapies are the primary systemic intervention for patients with estrogen receptor-positive (ER þ ) breast cancer. 
Introduction
Breast cancer is the most prevalent cancer in females worldwide. Estrogen signaling and estrogen receptors (ER) play a pivotal role in the initiation and progression of breast cancer, with the majority of human breast cancer being initially estrogen dependent. In accepted models of ER function, estrogen binding to either ERa or ERb results in dimerization and conformational change (1) . The resulting estrogen-ER complex modulates gene transcription by binding to estrogen response elements in DNA, or by interaction with other transcription factors such as specificity protein 1 (SP1), activating protein 1 (AP-1), or NF-kB (2) . ER signaling can also be modulated by other coregulatory proteins or through genomic and extranuclear actions (3, 4) . Expression arrays have identified early and late estrogen responsive genes (5), including genes involved in cancer cell proliferation and survival, enhancing our understanding of the molecular events involved in estrogen action.
Antiestrogens remain the most effective form of systemic intervention for patients with ER-positive (ER þ ) tumors, which account for approximately 75% of breast cancers. Current approaches include the use of selective ER modulators (SERM; e.g., tamoxifen) that compete with estrogen for ER binding or aromatase inhibitors (e.g., letrozole, anastrozole, and exemestane), which inhibit the synthesis of estrogen. ERa, the currently used predictive biomarker for antiestrogen responsiveness, is not consistently accurate in predicting response due to de novo or acquired tumor resistance. Although a significant high proportion of ER eventually develops, and up to 40% to 50% of patients with ER þ tumors relapse (6) (7) (8) (9) , through molecular mechanisms
that are yet to be fully understood. These tumors typically continue to express ERa (10) and demonstrate earlier metastatic recurrence (11) . The expression of ERa-regulated progesterone receptor (PR) and BCL-2 genes is associated with improved survival of patients with breast cancer (12, 13) and serves as a favorable prognostic marker for endocrine therapy (12, 14) . However, there is still no definitive methodology to distinguish ER þ tumors that will or will not respond to endocrine therapy. There appears to be as few as 168 human-specific genes among the approximately 23,000 or so genes identified from the completion of the human genome project (15) . When expanded to include primate lineages, there may be only several hundred unique hominoid genes. The identification of such human/hominoid-specific genes and analysis of their molecular functions might increase the understanding of the contributions these genes likely make to human disease processes. Studies have demonstrated that some human/hominoid-specific genes and their regulated signaling pathways may serve as biomarkers in human disease (16) and a number of human/hominoid-specific genes, such as Tre2 (17) and TBC1D3 (18) (19) (20) , have been linked to human cancer. However, only a few proteins translated from human/hominoid-specific genes have been studied and the functions of many others remain as yet uncharacterized.
Here, we report the identification of a novel estrogen regulated oncogene, secreted hominoid-specific oncogene (SHON) in mammary carcinoma and determine the predictive significance of SHON expression for response to endocrine therapy in high-risk patients with ER þ breast cancer.
Materials and Methods

Cell lines
All cell lines used in this study were obtained from the American Type Culture Collection and were cultured in conditions as recommended except the MCF-7 cell line that was cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L L-glutamine in a 37 C humidified incubator with 5% CO 2 .
Plasmid constructs
PIKR2786 (Genentech UNQ ID: UNQ2786) represented by an expressed sequence tag (EST; GenBank AY358103) was originally identified, through bioinformatic analysis, as a potential secreted or transmembrane protein (21) . We have demonstrated that UNQ2786 is a secreted protein and is a human mammary epithelial oncogene and have named it as SHON. The human SHON-expressing plasmids were constructed by using a protocol previously described (22) . The Bcl-2 P1 promoter reporter plasmid (23) and the NF-kB reporter plasmid (24) were previously described.
Tumor xenografts in nude mice
The experimental protocols followed are described in the Supplementary Materials and Methods.
Clinical samples, patient data analysis, and ethics statement This study was approved by the Nottingham Research Ethics Committee 2. Immunohistochemical (IHC) staining was carried out using a cohort of breast tissue specimens from Nottingham, United Kingdom (25, 26) . Detailed patient demographics and clinicopathologic characteristics and methodology about these samples can be found in the Supplementary Materials and Methods.
A full description of the materials and methods used for this work is described in Supplementary Materials and Methods.
Results
Expression of SHON in human normal tissues and carcinoma cell lines
Sequence homology searches using National Center for Biotechnology Information (NCBI) basic local alignment search tool (BLAST) revealed that SHON belongs to a hominoid-specific gene family with no known orthologs outside the primate lineage. SHON contains a predicted open reading frame of 282 bp encoding a 93-amino acid residue protein with a predicted molecular mass of 9.7 kDa (Fig.  1A ). There is a possibility that an internal disulfide bond is formed between the two cysteines in the mature protein.
SHON gene expression was detected in all 48 human tissues in a commercially available panel of cDNAs after 40 cycles of PCR amplification (Fig. 1B) . SHON mRNA was also expressed in all cancer cell lines tested (Fig. 1C, top) .
A rabbit polyclonal antibody against the C-terminal of the predicted mature SHON protein was produced and its specificity was validated (Supplementary Figs. S1 and S2). A specific band of the approximate expected size (12 kDa) was detected in Western blot analysis in all cancer cell lines tested (Fig. 1C,  bottom) . However, no SHON protein expression was detected in the normal human mammary epithelial cell line, MCF10A ( Supplementary Fig. S2D ).
SHON is a secreted protein
SHON is predicted to be a secreted protein with a leading signal peptide encompassing amino acid residues 1 to 21 by SignalP 3.0 ( Fig. 1A; ref. 27 ). HIS-tagged SHON protein can be readily detected in both the whole cell lysate and the conditioned media by Western blotting (Fig. 1D ).
Forced expression of SHON increases mammary carcinoma cell growth
MCF-7 cells were stably transfected with the SHON expression plasmid pIRESneo3-SHON (designated MCF7-SHON) or with the empty vector pIRESneo3 (MCF7-Vec; Fig. 2A ). Forced expression of SHON also resulted in increased SHON protein in conditioned media ( Fig. 2A) .
Forced expression of SHON in MCF-7 cells significantly increased cell number under serum-replete (10% FBS; Fig.  2B ) and under serum-reduced (0.2% FBS) conditions (Fig.  2C ). Forced expression of SHON in MCF-7 cells not only decreased apoptotic cell death (Fig. 2D ), but also increased entry into S-phase (Fig. 2E ).
Forced expression of SHON promotes anchorageindependent growth
Forced expression of SHON in MCF-7 cells increased the total cell number in suspension culture relative to the control cell line, MCF7-Vec, over 8 days (Fig. 2F) . In soft agar, forced expression of SHON increased the number of colonies formed compared with MCF7-Vec cells (Fig. 2G ).
Forced expression of SHON enhances cell migration and invasion SHON increased MCF-7 cell migration in MCF7-SHON cells versus the control cell line MCF7-Vec (Fig. 2H) . The invasive capacity of MCF7-SHON cells over 48 hours was enhanced compared with the control cell line MCF7-Vec (Fig. 2H) . Complete wound healing occurred within 72 hours for the MCF7-SHON cell line, but not in the MCF7-Vec cell line (Fig.  2I ). Forced expression of SHON therefore enhanced the motility and invasive capacity of MCF-7 cells.
MCF7-Vec cells grew in clumps with prominent cell-to-cell contacts in 2D and 3D cultures, typical of an epithelial phenotype, whereas MCF7-SHON cells were scattered, displayed little intercellular contacts, and formed long cellular protrusions and filopodia, indicating an invasive phenotype (Fig. 2J) .
SHON-stimulated oncogenicity in mammary carcinoma cells is mediated by BCL-2 and NF-kB
Quantitative PCR was performed to examine the effect of forced expression of SHON on the relative expression levels of key genes involved in cell proliferation, survival, oncogenic transformation and growth (Supplementary Table S3 p85] of the PI3K/AKT/mTOR signaling pathway, and TGFB in the TGF-b pathway.
We conducted further analyses to elucidate the roles of BCL-2 and NF-kB in SHON-mediated oncogenicity. Significantly higher luciferase activity of the Bcl-2 gene P1 promoter was observed in MCF7-SHON cells than in the MCF7-Vec control cells (Fig. 3A) , indicating that SHON expression increased the transcriptional activation of the Bcl-2 gene. SHON expression also resulted in increased BCL-2 protein expression in MCF-7 cells relative to the control (Fig. 3B ). YC137 is a BCL-2-specific Cell number was determined at the indicated days. D, serum starvation-induced apoptosis was assessed with fluorescein isothiocyanate-conjugated Annexin V and propidium iodide. Apoptotic cells at both early (Annexin V-positive and propidium iodide-negative) and late (Annexin V-and propidium iodide-positive) stages are presented with the percentage. E, S-phase entry was assessed by BrdUrd incorporation assays. F, suspension culture. Cells were grown on the poly-HEMA-coated plates and cell number was determined at the indicated days. G, soft agar assays. Cells were seeded in 0.35% agarose and colonies formed were counted after incubation for 14 days. H, cell migration and invasion were determined by use of Transwell inserts as described in Materials and Methods. I, wound healing assays. Photographs were taken at the time indicated. Bar, 100 mm. J, morphology of stable MCF7-SHON (SHON) and MCF7-Vec (Vector) cells was examined in two-dimensional (2D) cultures and three-dimensional (3D) cultures in 4% growth factor-reduced Matrigel by visualization of actin filaments using fluorescein isothiocyanate-phalloidin labeling (green) and cell nuclei were stained with Hoechst 33258 (blue). Bar, 10 mm, ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. inhibitor (28). YC137 not only reduced the colony formation of both MCF7-Vec and SHON cells in a dose-dependent fashion, but also largely attenuated the SHON-stimulated enhancement of the anchorage-independent growth of MCF7-SHON cells, indicative of BCL-2 dependence of SHON-stimulated soft agar colony formation (Fig. 3C) . Furthermore, YC137 also largely abrogated the SHON-stimulated enhancement of MCF7-SHON cell growth in 3D Matrigel although significant inhibition of MCF7-Vec cell growth was also observed as expected (Fig. 3E) . SHON expression significantly increased NF-kB luciferase reporter activity (Fig. 3A) , indicating the activation of NF-kB pathways. The NF-kB pathways include classic and alternative pathways using NF-kB precursor proteins, p105 (NFkB1) and p100 (NF-kB2), respectively. SHON increased the expression of NF-kB1 (both p50 and its precursor p105) as well as its phosphorylated form (phospho-p105), but did not affect p100 (NF-kB2) expression (Fig. 3B) , indicating SHON activated the classic NF-kB pathway. Activation of the classic pathway involves the release of p50-p65 (Rel-A) from the inhibitory protein IkB, as a result of phosphorylation of IkB by IkB kinase and degradation of IkB by the proteasome. SHON increased the expression of p65 and phospho-p65 (Fig.  3B) . Activation of NF-kB is achieved primarily through the proteolytic degradation of IkB triggered by IkB phosphorylation at specific N-terminal residues. SHON increased the level of phospho-IkB although total IkB expression remained unchanged (Fig. 3B) . NF-kB resides in the cytoplasm in an inactive form and once activated following IkB degradation, the NF-kB complex undergoes translocation to the nucleus. SHON expression resulted in a constitutive p65 translocation into the nuclei in MCF7-SHON cells, whereas a predominant cytoplasmic p65 localization was observed in the control cell line, MCF7-Vec (Fig. 3G) . Both Akt and p44/ 42 (ERK1/2) mitogen-activated protein kinases (MAPK) play a crucial role in the activation of NF-kB (29, 30) . SHON expression significantly increased the expression of total AKT and phosphorylated AKT (phospho-AKT) as well as total p44/42 and phosphorylated p44/42 (phospho-p44/42) MAPK (Fig. 3B) .
BMS-345541 is an NF-kB-specific inhibitor and inhibits IkB kinase thereby blocking NF-kB activation (31) . BMS-345541 demonstrated a dose-dependent inhibition of colony formation in soft agar in both MCF7-Vec and MCF7-SHON cells (Fig. 3D) . At a concentration of 10 mmol/L, BMS-345541 largely abrogated the SHON-induced increase in colony formation of MCF7-SHON cells in soft agar (Fig. 3D) and the SHON-induced increase in MCF7-SHON cell growth in 3D Matrigel (Fig. 3F) , compared with the control cell line, MCF7-Vec.
SHON transforms the normal human breast epithelial cell
We stably expressed SHON in MCF10A cells (Fig. 4A) . Compared with the control cell line MCF10A-Vector, SHONoverexpressing MCF10A-SHON cells displayed a more scattered morphology with reduced cell-to-cell contact (Supplementary Fig. S3 ). When cultured in 3D Matrigel, MCF10A-Vector cells formed typical acini consisting of regular spherical structures with a hollow lumen. In contrast, MCF10A-SHON cells formed large disorganized multiacinar structures with filled lumina (Fig. 4B) . Furthermore, SHON dramatically enhanced anchorage-independent growth as indicated by colony formation in soft agar (Fig. 4C) .
Forced expression of SHON promotes MCF-7 tumor xenograft growth in vivo
In a tumor xenograft mouse model, both MCF7-SHON and MCF7-Vec cells formed palpable and measurable tumors, but MCF7-SHON cells formed faster growing and larger tumors compared with the MCF7-Vec cells (Fig. 4D) . Statistically significant enhancement of tumor volume was achieved after 1.5 weeks, and tumors formed by MCF7-SHON cells were larger in size by 36.0% compared with tumors formed by MCF7-Vec cells after 6.5 weeks. Tumors formed by MCF7-Vec cells were well differentiated and cellular, whereas those formed by MCF7-SHON cells were poorly differentiated and diffuse (Fig.  4E) . The MCF7-SHON tumors exhibited a higher percentage of bromodeoxyuridine (BrdUrd)-labeled nuclei (Fig. 4F ) and fewer terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells compared with the MCF7-Vec tumors (Fig. 4G) .
SHON mRNA is expressed in normal and cancerous breast tissues SHON mRNA was expressed in both normal and breast cancer tissues in a commercially available Breast Cancer cDNA Array (Fig. 5A) . However, an increased SHON mRNA expression was observed in cancer tissues compared with the normal breast tissues. Moreover, the expression level of SHON mRNA was positively correlated with higher cancer stages (Fig. 5A,  bottom) .
SHON expression is strongly correlated with hormone receptor status and BCL-2 expression in breast cancer tissues
We next performed a large-scale IHC analysis of SHON protein in mammary carcinoma using tissue microarrays (25, 26) . A total of 1,237 tumors were suitable for analysis of SHON expression. Sixty-two percent (766 of 1,237) of the tumors were SHON positive (Supplementary Table S5 ). The associations of SHON expression in breast cancer with clinicopathologic features are presented in Supplementary Table  S7 . Notably, SHON expression was highly positively correlated with hormone receptor status, i.e., ER þ /PR þ and AR þ (androgen receptor-positive), and BCL-2 expression, whereas SHON was negatively correlated with both EGFR and HER2 overexpression and the triple-negative phenotype.
Prognostic significance of SHON expression for response to endocrine therapy in ER þ high-risk breast cancer patients Multivariate Cox regression analysis revealed that SHON was an independent predictor for clinical outcome in the studied cohort of patients with breast cancer (Supplementary Table S8 ). Moreover, SHON protein expression was found to be a prognostic marker for response to endocrine therapy for patients whose tumors were ER þ and categorized as high risk (Nottingham Prognostic Index ! 3.4). Endocrine therapy-treated patients with tumors negative for SHON expression had a 2-fold increase in risk of death [HR, 2.1; 95% confidence interval (CI), 1.4-3.1; P < 0.0001], recurrence (HR, 1.9; 95% CI, 1.4-2.6; P < 0.0001), and distant metastasis (HR, 1.8; 95% CI, 1.2-2.5; P ¼ 0.007) at 10 years compared with patients whose tumors were positive for SHON expression (Fig. 5B) . SHON expression was not significantly related to disease-free survival in the ER À patient cohort with or without anthracycline treatment (Supplementary Fig. S7 ).
SHON is an estrogen inducible gene E2 treatment of ER þ MCF-7 cells resulted in increased SHON
mRNA and protein expression ( Supplementary Fig. S8A and S8B). Upon E2 treatment, a synergistic increase in cell number was observed in MCF7-SHON cells compared with MCF-Vec cells, whereas the ER pure antagonist ICI 182780 partially attenuated SHON-stimulated growth advantages in MCF-7 cells, indicating that SHON signaling is at least in part mediated by ER (Supplementary Fig. S8C ).
Depletion of endogenous SHON by siRNA significantly inhibits cell growth, anchorage-independent growth, and cell migration and invasion in MCF-7 cells A stable MCF-7 cell line (MCF7-siRNA) in which endogenous SHON expression was depleted by a SHON-specific siRNA plasmid and a control cell line (MCF7-CK) stably transfected by the negative control siRNA plasmid were established (Fig.  6A) . SHON depletion also reduced SHON protein secreted into conditioned media. Depletion of endogenous SHON decreased MCF-7 cell number in serum-replete conditions (Fig. 6B) and significantly increased apoptotic cell death induced by serum deprivation (Fig. 6C) . The volume of tumors was measured over a period of 6 weeks. E, histologic staining of representative tumors with hematoxylin and eosin. Bar, 100 mm. F, S-phase entry was assessed to measure the cell proliferation by BrdUrd incorporation assays at the end of the experiment. G, TUNEL assays were applied to determine apoptosis. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. Depletion of SHON significantly reduced the number of colonies formed in soft agar (Fig. 6D) and cell migration/ invasion (Fig. 6E) . SHON-depleted MCF7-siRNA cells also displayed a significant reduction in wound-induced migration (Fig. 6F) . Moreover, the colonies formed by MCF7-siRNA cells in 3D Matrigel were much smaller than the MCF7-CK cells (Supplementary Fig. S9 ).
Concordantly, depletion of endogenous SHON in MCF-7 cells significantly decreased BCL-2 gene transcription and protein expression (Supplementary Fig. S10) . Moreover, the transcriptional activity of NF-kB was decreased as a result of SHON depletion in MCF-7 cells (Supplementary Fig.  S10A ). Consistently, depletion of SHON expression decreased the protein expression of NF-kB1 (p50 and p105), p65, and IkB, as well as the phosphorylation of these key proteins in the NF-kB signaling pathway ( Supplementary  Fig. S10B ).
We also established another SHON-depleted MCF-7 cell line using the second most effective siRNA, which also exhibited similar inhibitory effects on cell growth, anchorage-independent growth, and cell migration/invasion in MCF-7 cells (Supplementary Fig. S11 ). Functional inhibition of SHON in MCF-7 cells using a polyclonal antibody reduces growth in 3D Matrigel and impairs cell invasion Consistent with the effect of siRNA, a rabbit polyclonal antibody to SHON inhibited MCF-7 cell invasion in a dosedependent manner (Fig. 6G) . The 3D Matrigel growth of both MCF7-Vec and MCF7-SHON was significantly inhibited by the polyclonal antibody (Fig. 6H) . Hence, SHON functions as a secreted protein. Fig. S12B ) and growth in 3D Matrigel ( Supplementary Fig. S12D ). Concordantly, depletion of SHON in T47D cells reduced colony formation in soft agar and growth in 3D Matrigel ( Supplementary Fig.  S12C and S12E). Furthermore, forced expression of SHON in T47D increased BCL-2 expression and activated NF-kB pathways ( Supplementary Fig. S13A ), which were shown to mediate the anchorage-independent growth of T47D as demonstrated in soft agar assays (Supplementary Fig.  S13B and S13C).
Secreted SHON promotes the growth and migration of MCF-7 and T47D cells As SHON is a secreted protein, coculture assays were used to determine whether SHON could function in a paracrine fashion. As shown in Fig. 7 , SHON secreted from MCF7-SHON stable cells promoted growth of both MCF-7 and T47D cells and also served as a chemoattractant to enhance cell migration of both MCF-7 and T47D cells.
Discussion
Our results presented here have demonstrated that SHON is a novel hominoid-specific gene that enhances oncogenicity of mammary carcinoma cell lines. Clinically, expression of SHON (32, 33) . In addition to the classic genomic action associated with nuclear ER, nongenomic ER action has also been reported: cell membrane or cytoplasm-associated ER promotes cellular signaling by direct interaction with a variety of signaling pathways (34) . Hence, ER directly associates with many key signaling molecules such as c-Src, Shc, and the p85a regulatory subunit of PI3K and modulates important secondary signaling messengers and downstream kinase pathways, such as the p21 Ras /p 44/42 MAPK and AKT, leading to, among other cellular processes, cell proliferation and survival (35) . In the present study, we have demonstrated that forced expression of SHON increased phospho-AKT and phospho-p 44/42 MAPK as well as total AKT and MAPK levels, and that the oncogenicity of SHON is mediated by BCL-2 and NF-kB signaling pathways. AKT is the cellular homolog product of the v-akt oncogene and is activated downstream from PI3K by multiple oncogenic growth factors and cytokines (36) . AKT itself activates multiple downstream effectors and mediates multiple pathways promoting angiogenesis, tumor progression, and metastasis. Activation of the PI3K/AKT/mTOR pathway has been reported in various human cancers and contributes to breast cancer progression. AKT can also activate NF-kB leading to the transcription of antiapoptotic and proinflammatory genes (37). BCL-2 is shown to function as an activator of the AKT signaling, and BCL-2 can also activate NF-kB through the activation of IkB kinase (IKK, a downstream target of AKT; ref. 38) or through the degradation of the NF-kB inhibitor IkBa (39) . Conversely, BCL-2 is transcriptionally regulated by NF-kB (40) and BCL-2 activity is enhanced by AKT phosphorylation of BAD and BAX (41) . Therefore, SHON may modulate ER signaling through the activation of p 44/42 MAPK, PI3K/AKT/mTOR pathways and NF-kB transcriptional activation of BCL-2. Indeed, we observed synergistic increases in cell number when cells with forced expression of SHON were concomitantly treated with estrogen.
Acquired resistance to antiestrogens remains a major obstacle for the successful management of ER þ breast cancer.
Several molecular mechanisms have been proposed to be responsible for antiestrogen resistance (7, 10) . However, the precise mechanisms remain uncertain. is an important promoter of cell survival and is overexpressed in 50% to 70% of solid malignancies, including breast cancer (44) . Although BCL-2 facilitates the survival of tumor cells, its expression has been consistently associated with a better prognosis in breast cancer (12) . This has been partly attributed to its correlation with favorable prognostic features such as ER/PR positivity (45), low proliferation index, absence of HER2 amplification, and mutant p53 expression (46) . We have observed that SHON increased the expression of BCL-2 and its upstream regulator NF-kB in vitro, and SHON expression is significantly and positively associated with BCL-2 expression in breast cancer. Therefore, SHON may exert its predictive value via the enhanced expression of BCL-2/NF-kB. However, the role of SHON and its mechanisms in endocrine therapy response needs further investigation. For example, forced expression of SHON in ER þ MCF-7 cells increased the transcriptional activation of NF-kB and activated the PI3K/AKT/ mTOR pathway. However, increased NF-kB activity has been reported to be associated with antiestrogen resistance and inhibition of NF-kB activity restored the sensitivity of resistant MCF-7 cells to antiestrogens (47) . In addition, extensive evidence suggests that the PI3K/AKT/mTOR pathway is linked to resistance to tamoxifen. In ERa-positive breast cancers treated with tamoxifen, AKT activation was associated with poor survival (48) and patient relapse (49) . In contrast, activation of AKT was reported to be associated with favorable outcomes in non-small cell lung cancer (49) . Therefore, whether that compartmentalization of SHON may be important in determining its prognostic effects via activation of AKT requires further investigation. Figure 7 . Secreted SHON promotes the paracrine growth and migration of MCF-7 and T47D cells. A, MCF-7 and T47D wild-type cells were plated on 24-well plates, whereas MCF7-Vec (Vector) or MCF7-SHON (SHON) stable cells were cocultured in serum-free media on cell culture inserts. After 5 days, cell number of the wild-type cells was determined. B, cell migration of MCF-7 and T47D cells was determined using Transwell inserts as described in Materials and Methods except that MCF7-Vec (Vector) and MCF7-SHON (SHON) cells were grown in serum-free media on the bottom wells. Migrated cells were counted after 24 hours (MCF-7) or 48 hours (T47D).
